WHO rates the risk as very high in the Democratic Republic of the Congo, high in countries sharing land borders with it and low for the rest of Africa and the global level. The low global assessment reflects the absence of sustained transmission outside the Democratic Republic of the Congo—not the absence of imported cases or the possibility of further spread.

What changed on August 24

WHO’s second International Health Regulations emergency-committee meeting took place on August 18. After reviewing the outbreak, the WHO director-general issued updated temporary recommendations on August 24 for three groups of countries: the Democratic Republic of the Congo, countries with land borders adjoining it and all other countries.

For the Democratic Republic of the Congo, the recommendations provide more detailed guidance on surveillance, case detection, laboratory testing, infection prevention, clinical care, community engagement and health-worker protection. They also add or strengthen measures involving schools, mass gatherings, domestic mobility, road checkpoints and surveillance on inland waterways.

WHO also calls for daily reporting of suspected, probable and confirmed cases, 21-day monitoring of contacts after their last known exposure, safe and dignified burials, expanded testing capacity, protection and support for health workers, and information-sharing with neighboring countries when contacts cross borders.

The framework formalizes preparedness and coordination under the International Health Regulations. It does not impose a blanket international travel or trade ban. WHO’s recommendations say that suspension of flights or waterways routes and denial of entry to travelers from countries with community transmission are not recommended at this stage.

How large is the outbreak?

WHO’s latest detailed rapid risk assessment, covering data through August 13, recorded 4,566 confirmed cases and 2,128 deaths across six provinces and 54 health zones, a 47% crude case-fatality ratio.

The affected provinces are Ituri, North Kivu, South Kivu, Haut-Uélé, Tshopo and Bas-Uélé. Ituri remains the epicenter and has strong connections to Uganda and South Sudan through population movement, trade, mining and displacement.

Those WHO figures are not the same reporting snapshot as the newest national update. An Associated Press report published August 28, citing Congolese government figures, said the outbreak had reached 60 health zones, with 5,794 confirmed cases and 2,786 deaths. The totals differ because they cover different dates and reporting systems; the newer figures should not be presented as a direct correction to WHO’s August 13 assessment.

Why borders remain central

People move across the region’s formal and informal borders for work, trade, school, health care, family visits and refuge. That movement increases the chance that an infected person could reach a neighboring country before symptoms are recognized or contacts are identified.

WHO has documented imported cases in Uganda and France. It also reported that two patients diagnosed in the Democratic Republic of the Congo were subsequently treated in Germany. Sustained transmission has not been established outside the Democratic Republic of the Congo.

Uganda remains a particular preparedness focus because of its proximity to Ituri and its links to the affected area through trade, displacement and routine travel. WHO says Uganda’s monitoring and surveillance activities remain important because reintroduction remains possible while transmission continues across the border.

For travelers, aid groups and organizations operating in or near affected areas, the practical effect is stronger screening, information-sharing, contact follow-up and readiness measures—not an automatic shutdown of international travel.

A response constrained by insecurity and limited tools

WHO says there is currently no approved Bundibugyo-specific vaccine or therapeutic. Response teams therefore depend heavily on early detection, supportive care, infection prevention, contact tracing, safe burials and community cooperation.

The Democratic Republic of the Congo has begun vaccinating health workers and other frontline workers with Ervebo, a vaccine developed for a different Ebola virus. Its use should not be confused with an approved vaccine specifically for Bundibugyo virus. WHO-backed clinical trials are evaluating potential treatments, but investigational therapies are not the same as licensed standard treatment.

Operational conditions make the public-health measures harder to deliver. WHO and Africa CDC have highlighted insecurity, attacks affecting health facilities, infections among health workers, displacement, mistrust and funding gaps. The Associated Press also reported that a health-worker strike and intense population movement were complicating the response. These pressures can delay diagnosis, interrupt contact monitoring and reduce access to care.

What to watch next

The next indicators are the number of newly affected health zones, infections among health workers, additional imported cases, any sustained transmission outside the Democratic Republic of the Congo and whether international funding and response capacity expand.

The immediate humanitarian danger remains concentrated inside the Democratic Republic of the Congo, especially in Ituri and other affected provinces, even as the wider global risk assessment remains low. For neighboring countries, the priority is readiness: detecting imported cases quickly, tracing contacts across borders and keeping health systems prepared without disrupting essential movement and care.

Sources

• WHO emergency recommendations, Aug. 24, 2026
• Associated Press outbreak update, Aug. 28, 2026

The same-day developments show both how rapid detection and containment can stop transmission and how limited the available countermeasures remain against Bundibugyo ebolavirus, the strain involved in both outbreaks.

Uganda completes the final countdown

The World Health Organization and Africa Centres for Disease Control and Prevention said Uganda had met the international benchmark for ending transmission linked to an Ebola outbreak. The 42-day period is twice the upper limit of Ebola’s incubation period and is used as an added safeguard against undetected chains of transmission.

Uganda’s last patient, an imported case from the Democratic Republic of the Congo, was discharged on July 16. Uganda announced that local transmission had been interrupted on July 28, but continued surveillance and completed the additional 42-day monitoring period before declaring the outbreak over on August 27.

Uganda recorded 20 confirmed cases, including 15 imported from the Democratic Republic of the Congo and five locally acquired among contacts and health workers linked to imported cases. Eighteen people recovered and two died. More than 800 contacts were identified and monitored.

According to WHO, the response relied on case detection and confirmation, contact tracing, isolation, clinical care, infection-prevention measures, community engagement, surveillance in health facilities and monitoring at points of entry. The declaration does not mean Uganda is permanently free of Ebola. Surveillance, testing capacity and cross-border preparedness are continuing.

Congo launches vaccination in Kisangani

On the same day, Congo officially launched an Ebola vaccination campaign in Kisangani, the capital of Tshopo province. Health workers, other frontline responders and people who had contact with Ebola patients were among the first groups prioritized.

The campaign is expected to cover 14 health zones in Tshopo, Bas-Uélé and Haut-Uélé provinces. The Associated Press reported that more than 50,000 doses had been received, while WHO had approved 70,000 doses for use in Congo.

About 50,000 doses are intended for frontline and health workers. Another 20,000 are intended for a clinical trial examining whether Ervebo can protect against Bundibugyo Ebola, according to AP’s reporting on WHO and African health officials.

Why Ervebo is being studied

The vaccine being used, Ervebo, is approved to protect against Zaire ebolavirus. It is not specifically approved for Bundibugyo ebolavirus, the strain identified in the current outbreaks.

WHO says there is no vaccine specifically approved for Bundibugyo Ebola and no specific treatment for the strain. Ervebo is therefore being used under a compassionate-use program while researchers collect data on whether it provides protection against this different virus.

Health authorities say the two viruses are related and that Ervebo could offer some protection, but its ability to prevent illness from Bundibugyo Ebola remains under study. The vaccination campaign should not be treated as proof that the vaccine is effective against this strain or that Congo has contained the outbreak.

Congo’s outbreak remains active and expanding

WHO’s weekly situation report, using data through August 23, recorded 5,584 confirmed cases and 2,680 confirmed deaths in Congo. The agency said the outbreak had expanded from 55 to 57 affected health zones across six provinces.

The Associated Press, citing newer Congolese government figures, reported 5,713 confirmed cases and 2,744 deaths as of August 25. The different totals reflect the separate reporting cutoff dates.

AP reported that the affected provinces include Ituri, North Kivu, South Kivu, Tshopo, Haut-Uélé and Bas-Uélé. WHO has described the outbreak as involving sustained transmission, high mortality and continued geographic expansion, with insecurity, displacement, humanitarian pressures and population movement complicating the response.

What it means for the region

Uganda’s milestone demonstrates the value of early case detection, contact tracing, isolation, clinical preparedness and community cooperation. But the outbreak’s cross-border origin and Congo’s continuing transmission mean neighboring countries remain at risk of imported cases.

WHO continues to advise against broad travel and trade restrictions related to the outbreak. It does not recommend suspending flights, closing borders or denying entry to travelers from affected countries. Instead, countries are being urged to maintain proportionate measures such as surveillance, rapid alert investigation, testing, infection prevention and cross-border coordination.

For travelers, businesses and communities, that means there is no general regional border shutdown under current guidance, although requirements and precautions in directly affected areas may change as health authorities receive new information.

Sources

• WHO Africa: Uganda ends Ebola outbreak following completion of 42-day countdown
• Associated Press: Health workers in Congo receive Ebola vaccine amid outbreak

The United Nations identifies Otunnu’s nomination date as July 24, 2026. The joint letter transmitting the nomination is dated July 27. The distinction matters because Otunnu entered after the General Assembly’s scheduled public interactive dialogues had already begun and as the Security Council moved into its consideration phase.

Otunnu’s entry does not establish him as a front-runner. The Associated Press reported that there is no clear favorite in the contest, which is shaped by diplomatic bargaining rather than a worldwide public vote.

Who is in the field

The United Nations publicly lists seven active candidates:

• Michelle Bachelet of Chile
• María Fernanda Espinosa of Ecuador
• Rafael Mariano Grossi of Argentina
• Rebeca Grynspan of Costa Rica
• Olara Otunnu of Uganda
• Carolyn Rodrigues Birkett of Guyana
• Macky Sall of Senegal

The U.N. record contains inconsistent display text for Rodrigues Birkett’s nomination date. The Guyana nomination letter identifies June 15, while another page heading shows June 25. The document-supported date is June 15.

This is not a popular election

The secretary-general is not chosen through a direct public vote. Member states nominate candidates, who provide public documents and take part in interactive dialogues intended to give the broader U.N. membership an opportunity to examine their experience and priorities.

The process began with a joint General Assembly-Security Council letter published on November 25, 2025. The General Assembly’s role includes circulating candidate materials, organizing public dialogues and facilitating wider member-state engagement.

Under Article 97 of the U.N. Charter, the 15-member Security Council recommends a candidate to the General Assembly. Its five permanent members — the United States, Russia, China, the United Kingdom and France — can block a candidate by withholding the agreement needed to avoid a veto. The 10 elected members also participate in the Council’s consideration.

After the Council makes a recommendation, the 193-member General Assembly makes the formal appointment. The Assembly does not independently choose among all candidates in a direct contest; its action follows the Council’s recommendation.

Why straw polls matter

Security Council straw polls are informal consultations, not binding votes or a final selection. They can indicate support, opposition or no specific opinion and help diplomats assess whether a candidate has enough backing to remain viable.

The U.N. has documented the start of the Council’s consideration phase, but the approved record does not show that the Council has selected a nominee. The next meaningful developments will come from internal Council consultations, possible straw polls and, eventually, a formal recommendation.

Regional tradition matters, but it is not a rule

The secretary-general’s post has often followed an informal regional rotation. Latin America and the Caribbean are widely viewed as having the strongest regional expectation in this cycle, putting several candidates from that region in a politically favorable position.

Regional rotation is a diplomatic convention, not a legal requirement. It cannot formally disqualify a candidate from Africa or another region. Otunnu’s nomination also shows that governments can continue adding candidates after public events have begun because the process does not impose a hard formal nomination deadline.

For readers trying to understand what happens next, the key point is that the outcome will be decided through two linked stages: the Security Council must recommend one candidate without a veto from any permanent member, and the General Assembly must then make the formal appointment. Uganda’s late-July nomination widened the field, but it did not resolve the contest.

Sources

• United Nations: Selection and Appointment of the Next Secretary-General
• Associated Press: Ugandan statesman enters U.N. secretary-general race

The entrant is seeking to succeed António Guterres, who is due to leave the post at the end of 2026. The announcement adds a new candidate to a contest that will determine who leads the United Nations after Guterres’s tenure.

A seven-candidate contest

The entry from Uganda is an announcement of a candidacy, not a final selection. It does not establish a front-runner or show that the candidate has secured backing from Uganda’s regional partners or from members of the Security Council.

The reported seven-candidate field reflects a contest that is already underway. Candidates are seeking an office whose selection involves the United Nations’ 15-member Security Council and the General Assembly. The process therefore requires consideration within the U.N. system rather than a decision by a single national government.

The Security Council has five permanent members: the United States, Russia, China, the United Kingdom and France. Those five countries hold veto power, giving them a distinct role in the council’s consideration of the next secretary-general alongside the council’s other members.

The General Assembly is also involved in selecting the secretary-general. Its participation places the succession within the wider membership of the United Nations, while the Security Council remains central to the process.

Why the office matters

The next secretary-general will lead the United Nations during major conflicts, humanitarian emergencies and diplomatic disputes. The choice will therefore shape who serves as the organization’s senior diplomatic voice during international crises.

The office also sits within a system where major decisions depend on cooperation among member states with competing interests. The Security Council’s structure is especially important to the succession because its five permanent members can use their vetoes, making their position consequential in the council’s role in the selection.

For Uganda, the announcement places a national candidate in a global contest for an office that serves the entire United Nations. The candidacy gives Uganda a place in the succession debate, but the announcement itself does not determine how much support the candidate will receive or whether the candidacy will advance to the final decision.

What happens next

Guterres is scheduled to remain in office through the end of 2026. The public report does not set out a final shortlist or a voting timetable, leaving the next formal milestones in the succession process unsettled.

The immediate development is the expansion of the field. With seven candidates reported, the contest will continue through the U.N. process involving the Security Council and General Assembly before a successor is chosen.

The selection will be watched not only as a change in personnel but also as an indication of how member states weigh competing priorities for the organization’s next leader. The eventual choice will determine who represents the United Nations at a time defined by the conflicts, emergencies and diplomatic disputes the secretary-general is expected to address.

The outbreak began in Ituri Province and has also raised cross-border concerns after two laboratory-confirmed cases were reported in Kampala, Uganda, in May. One of those patients died. The people were traveling from the Democratic Republic of the Congo, according to WHO.

WHO has urged authorities in both countries to maintain surveillance, confirm suspected infections in laboratories, strengthen infection prevention and control, expand treatment capacity and monitor people who may have been exposed.

Outbreak began in Ituri Province

The Democratic Republic of the Congo confirmed the outbreak in May 2026 in the Rwampara and Mongbwalu health zones of Ituri Province. The country’s health ministry officially declared it the Democratic Republic of the Congo’s 17th Ebola outbreak.

The virus involved is Bundibugyo virus, a distinct Ebola species. The outbreak’s location and movement of people between Congo and Uganda have complicated the response, making early detection and coordination across borders important even as health officials work to determine where transmission is occurring.

WHO said the latest confirmed case cited in its July update was identified on June 21. That patient recovered and was discharged. The agency said, however, that confirmed cases and deaths in the Democratic Republic of the Congo had risen substantially since the preceding update.

The July update did not present a complete current total in the information publicly summarized by WHO, so the scale of the increase cannot be expressed here as a single case or death figure. The reported rise, along with the continuing need for contact monitoring and laboratory confirmation, indicates that response teams are still working to identify infections and interrupt transmission.

Uganda reported cases in Kampala

Uganda’s cases prompted WHO to issue recommendations covering isolation, diagnosis, contact tracing, monitoring and safe burials. The Kampala infections demonstrated the practical cross-border risk associated with travel from the outbreak area, while not establishing sustained community transmission across every affected location.

WHO declared the epidemic a public health emergency of international concern on May 17, 2026. That designation is used for events that pose a risk of international spread and may require a coordinated international response. The decision brought heightened attention to measures intended to limit further transmission between countries.

WHO has described the response as involving rapid-response teams, medical supplies, surveillance and laboratory work. Officials are also assessing infection-prevention and control practices, establishing safe treatment centers and engaging communities in affected areas.

Response challenges remain

Occupational exposure risks and inadequate infection-prevention controls are among the operational concerns identified in WHO’s outbreak update. Health workers and other responders depend on protective procedures, timely testing and safe treatment arrangements to reduce the risk of additional infections.

Reuters reported from Bunia that a WHO official said the outbreak was still spreading largely undetected, highlighting the challenge of finding cases that may not reach health facilities or be identified quickly. That concern makes surveillance and contact monitoring central to the next phase of the response.

The immediate next steps are continued case finding, laboratory confirmation, monitoring of contacts, infection-control assessments and treatment support in the Democratic Republic of the Congo and Uganda. WHO’s July 17 update did not announce an end date for those measures or declare the outbreak contained.

The force is part of a broader ceasefire arrangement reached the previous year, AP reported. That framework calls for Israel to cease military operations and for Hamas and allied groups to halt militant activity. Uganda’s approval is a government decision to participate; it does not establish that Ugandan troops have deployed.

What Uganda’s decision changes

Uganda’s action gives the proposed force another national commitment to build on as planners consider how security in Gaza could be organized after the fighting. It also places Uganda among the countries being associated with an international role in the territory’s postwar arrangements.

That distinction matters because the force remains proposed rather than operational in the information available. The report does not establish that the force has begun work in Gaza, that the ceasefire framework has been fully implemented, or that Uganda’s decision guarantees participation by other countries.

The approval therefore represents a step toward a possible international security presence, not the completion of one. The practical meaning of the decision will depend on whether the broader arrangement advances and on how a participating force would receive authority to operate.

Terms of the broader framework

The ceasefire and postwar framework described by AP assigns obligations to the main parties. Israel is called on to stop military operations. Hamas and allied groups are called on to stop militant activity.

Those provisions define the security environment the proposed force is intended to support, but the available report does not provide a full account of how compliance would be assessed or enforced. It also does not establish the current implementation status of the broader arrangement.

As a result, Uganda’s approval should be read alongside the framework’s unresolved practical questions. A commitment to send troops is different from an actual deployment, and a proposed international force is different from a functioning command with an agreed mission.

What remains unknown

The report does not specify how many personnel Uganda approved. It does not give a deployment date, rules of engagement or command structure. Those details would determine the scale of Uganda’s role and the authority under which its troops might operate.

The timing is also unresolved. No deployment has been established by the available reporting, and there is no confirmed next date in the source material for the force to begin operating. The next known step is therefore implementation work: determining whether the broader arrangement moves forward and, if it does, resolving the force’s composition, timing and authority.

For international observers, the decision is a sign that the proposed postwar structure may attract state participation. For readers following the conflict, however, the central question is not only who has offered troops. It is whether the ceasefire obligations, international force and command arrangements can be translated from a framework into an operating security system.

Uganda’s approval makes that question more immediate without answering it. Until the missing details are settled, the size, timing and operational reach of any Ugandan contribution remain unknown.

The update also records an international medical evacuation linked to the outbreak. Germany notified WHO on July 13 of a laboratory-confirmed case in a U.S. humanitarian worker who had been evacuated from the DRC for medical care.

WHO said the German case was the second U.S. citizen treated in Germany in connection with the response. The update does not establish that transmission occurred in Germany, and the case should not be described as evidence of community spread there.

What the latest figures show

The DRC figures are tied specifically to July 15. They count confirmed Bundibugyo virus disease cases and reported deaths; they do not represent the total number of suspected or probable infections.

WHO’s assessment that transmission remains active indicates that the outbreak is continuing inside the DRC. The combination of sustained transmission and the evacuation of an infected humanitarian worker also shows why health authorities must maintain surveillance and response measures across borders.

The 828 deaths reported in the update should not be used to calculate a final fatality rate. The outbreak is ongoing, the figures cover a defined reporting date, and the case and death totals may have changed after the WHO update.

Uganda reports no new cases

Uganda reported no new cases during the period covered by the update and has reported no new cases since June 21.

Its most recent case was discharged from a treatment center on July 16 after two negative tests. That is a significant development for Uganda’s response, but the available information does not establish that the country’s outbreak is formally over solely because no new cases were reported during the stated period.

The different situations in the DRC and Uganda underscore the need to distinguish between a country reporting no new cases during an update period and an outbreak being officially concluded. For readers following the international response, Uganda’s latest discharge is encouraging, while the DRC remains the center of active transmission described by WHO.

How the outbreak reached the international response stage

The DRC declared its 17th Ebola outbreak on May 15. Two days later, on May 17, WHO determined that the outbreak constituted a public-health emergency of international concern.

That designation and the subsequent evacuation to Germany place the current update in a broader cross-border context. The response involves the DRC, Uganda and Germany, as well as the United States because the evacuated worker is a U.S. citizen. It also requires health authorities to share information about cases and possible exposures while avoiding unsupported conclusions about where transmission occurred.

WHO’s July 17 update does not provide a new closing date for the emergency or a separate deadline for ending surveillance. The next known step is continued monitoring and response, particularly in the DRC, alongside cross-border attention to people connected with the outbreak.

The reported totals are therefore a status report, not a final account. The DRC case and death numbers reflect the situation as of July 15, Uganda’s no-new-case period has a stated endpoint of June 21, and the German notification concerns a medically evacuated worker rather than documented community transmission in Germany.

The test is designed to identify the virus’s genetic material in blood samples. WHO said the listing can support rapid and accurate confirmation, an important step for surveillance and containment when health officials are tracking a cross-border outbreak.

What the listing changes

An Emergency Use Listing is an authorization for use in an urgent public-health setting. It does not make the diagnostic test a vaccine or a treatment, and the source packet does not identify the manufacturer or product name.

The practical change is diagnostic capacity. Faster confirmation can help officials distinguish suspected infections from cases that require other explanations, while supporting the surveillance, contact tracing and infection-control measures WHO has emphasized in its outbreak guidance.

WHO’s action came after the agency declared a public health emergency of international concern over the outbreak on May 17, 2026. The outbreak is centered in the Democratic Republic of the Congo, with cases also reported in Uganda. The listing was issued as a global emergency-health action, but it does not establish that the virus is spreading globally.

No specifically licensed vaccine or treatment

WHO says there is no vaccine specifically licensed for Bundibugyo virus disease and no specific therapeutic for the illness. In guidance issued May 28, the agency discussed possible cross-protection from Ervebo, a licensed Ebola virus vaccine, while emphasizing surveillance, contact tracing, infection control and community engagement.

That distinction matters. The newly listed product is a diagnostic test intended to detect viral genetic material in blood; it is not an immunization and does not treat an infected patient. The approved material does not say that Ervebo has been specifically licensed for Bundibugyo virus disease or that the vaccine has ended the outbreak.

WHO reports additional U.S. case

In a July situation update, WHO reported that a second U.S. citizen, identified as a humanitarian worker, tested positive in the Democratic Republic of the Congo. The worker was medically evacuated to Frankfurt. The update means at least two U.S. citizens had tested positive by that point, according to the source summary.

The packet does not provide a total case count, and it does not establish how many infections occurred in each country. Those omissions limit what can be concluded about the outbreak’s size or trajectory.

What happens next

WHO assessed the risk to the rest of Africa and globally as low in its July update. That is the agency’s current assessment, not a declaration that the risk is zero. WHO also called for continued surveillance, cross-border coordination and preparedness.

The newly available diagnostic test is therefore one part of a broader response rather than a standalone solution. Health authorities still need to identify suspected cases, confirm infections, trace contacts and maintain infection-control practices. WHO’s guidance also highlights the importance of engaging affected communities.

Further epidemiological information could change the risk assessment. For now, the July 2 listing gives responders in the affected countries a first WHO-listed diagnostic option for detecting Bundibugyo virus, while the outbreak response continues without a specifically licensed vaccine or treatment for the disease.

But the proposal faces a central sequencing dispute. Israeli Prime Minister Benjamin Netanyahu said on August 4 that Israel would not withdraw from its current lines until Hamas had been completely disarmed. Under the framework described by the Associated Press, Israeli forces would withdraw in phases before the proposed international force entered Gaza.

That gap between the two positions leaves the proposed arrangement without a settled path to implementation. Uganda’s parliamentary approval authorizes a possible contribution, but it does not establish that Ugandan troops will deploy or that the international force is operational.

Uganda’s decision

The Ugandan approval concerns a proposed international stabilization force for Gaza. The force would be part of a plan addressing the territory’s postwar transition, rather than a completed peace agreement.

The reports supplied for this article do not specify how many Ugandan troops could be sent. They also do not establish the total size of the proposed force, its final membership, its mandate or a deployment date.

Those details matter because parliamentary approval is only one step in creating an international operation. The timing, force composition and operating authority remain unsettled, and it is not clear whether Uganda’s decision will result in an actual deployment.

The unresolved withdrawal question

Netanyahu’s August 4 statement directly challenged the sequencing associated with the U.S.-backed arrangement. According to the AP account, the proposed framework envisioned a phased Israeli withdrawal followed by deployment of the international force.

Netanyahu instead said Israel would not withdraw from its current positions until Hamas was completely disarmed. The AP report said he was pushing back on a recently announced U.S.-backed arrangement and faced an October reelection contest.

The disagreement is not a technical detail. If an international force is intended to enter only after an Israeli withdrawal, an Israeli condition requiring complete disarmament first could delay or prevent the force’s deployment. The approved source material does not establish whether the framework contains a mechanism to resolve that conflict.

Hamas’ stated condition

Hamas has described a different sequence. In an AP report published July 31, the group said it would disarm if Israel halted attacks and withdrew from Gaza.

That statement does not show that Hamas has accepted the proposed disarmament terms in full. It instead links disarmament to an Israeli halt in attacks and troop withdrawal, placing Hamas’ stated condition opposite Israel’s demand that disarmament come first.

The same report described obstacles to implementing the arrangement. It said a Palestinian technocratic committee was eager to enter Gaza but concerned about Israeli restrictions. The committee’s reported interest does not establish that it has entered the territory or that the proposed governance arrangements are in operation.

What happens next

The immediate next step is not a confirmed deployment but continued work on the unresolved framework. Uganda’s approval may provide a potential troop contribution, while the Israeli and Hamas positions leave the order of withdrawal, disarmament and international entry unsettled.

No deadline for deployment is identified in the approved reports. Until the force’s mandate, membership and timing are resolved—and until the dispute over whether withdrawal or disarmament comes first is addressed—the proposal remains an arrangement under negotiation rather than an operating international mission.

The warning, reported by The Associated Press on Aug. 5, describes a rapidly worsening public-health emergency in Ituri Province and eastern Congo. The outbreak involves the Bundibugyo virus, a species of Ebola virus for which there is no approved treatment or vaccine, according to AP.

AP reported that more than 1,700 people had died by Aug. 4. That figure is not a final official count: case and death totals are changing rapidly and should be reconciled with the newest WHO and Democratic Republic of the Congo Ministry of Health situation reports.

A response under strain

The outbreak’s spread is being compounded by weakened response capacity. Some health workers have stopped work because they have not been paid. The strike is one factor limiting containment efforts, but the available reporting does not establish it as the sole cause of the response problems.

AP also reported that more than 100 health-care workers had been infected since the outbreak began. The WHO’s early records documented infections among health workers and concerns about infection-prevention and control measures.

Africa CDC said that 60% to 70% of new cases were occurring outside monitored contacts. That estimate points to serious weaknesses in contact tracing: response teams are missing many people who may have been exposed, making it harder to identify infections before transmission continues.

Ebola is generally transmitted through direct contact with the bodily fluids of an infected person, according to a CDC field report. That makes surveillance, laboratory testing, infection prevention, safe care and border health measures central to containing the outbreak.

How the outbreak reached an international-alert stage

WHO’s initial alert came on May 5 after a high-mortality cluster was identified in Mongbwalu Health Zone in Ituri Province. The cluster included deaths among health workers.

After consulting affected states, WHO declared the outbreak a public health emergency of international concern on May 17 for the Democratic Republic of the Congo and Uganda. WHO records cover both countries, reflecting the cross-border implications of an outbreak centered in eastern Congo.

The source of the outbreak and the identity of the index case remain unresolved in the current reporting. The available evidence establishes the location, virus and response gaps, but it does not establish that the outbreak is uncontrolled everywhere in Congo or that there is international community transmission.

Why the virus and geography matter

The absence of an approved vaccine or treatment for the Bundibugyo strain leaves responders with fewer medical tools than they have for some other Ebola outbreaks. The combination of rapid transmission, infections among health workers, incomplete contact tracing and labor disruptions raises the risk of further spread within Congo and across borders into Uganda and neighboring countries.

For people outside the affected region, the emergency is also a test of international outbreak coordination. The CDC says an American who was exposed while working in the Democratic Republic of the Congo tested positive and was transported to Germany for care. The agency has issued U.S. travel and clinical guidance while coordinating with international partners.

CDC’s May 17 emergency response activation included cooperation on surveillance, laboratory testing, contact tracing, infection prevention and border health surveillance. Doctors Without Borders and Africa CDC have also provided response assessments cited by AP.

What happens next

WHO, Congo’s health authorities, Uganda and international responders must improve the identification and monitoring of contacts while maintaining safe care for patients and health workers. They also face the immediate challenge of restoring response capacity where unpaid workers are on strike.

The next reliable measure of the outbreak’s scale will be an updated WHO or national situation report that reconciles the rapidly changing case and death totals. No specific deadline for that update is stated in the approved reporting. Until then, the AP figure of more than 1,700 deaths should be treated as a reported interim estimate rather than a final official count.

The latest WHO report included another international health-worker development: a second U.S. citizen working as a humanitarian worker tested positive in the Democratic Republic of the Congo during July. The patient was medically evacuated to a university hospital in Frankfurt, Germany.

The available report does not provide the updated total number of confirmed cases or deaths in the source material reviewed for this article. The increase reported by WHO is therefore described as substantial without adding an unsupported numerical total.

An outbreak spanning two countries

WHO’s Director-General declared the epidemic in the Democratic Republic of the Congo and Uganda a public-health emergency of international concern on May 17, 2026. The designation is used for health events that carry potential international consequences and require a coordinated response across borders.

WHO said the determination did not meet the organization’s definition of a pandemic emergency. That distinction matters: the current designation signals serious international-health implications, but it does not mean WHO has classified the outbreak as a pandemic emergency.

The outbreak concerns Bundibugyo virus disease. It should not be treated as the same disease as Ebola virus disease caused by EBOV, even though the illnesses are related within the broader group of viral hemorrhagic fevers and the outbreak is commonly discussed in Ebola-response terms.

Health-worker exposure remains a concern

In its July 23 report, WHO identified persistent occupational exposure risks and inadequate infection-prevention and control practices as continuing concerns. Those risks are especially important in an outbreak involving health and humanitarian workers, who may come into contact with infected patients or contaminated materials while providing care and support.

The evacuation of the second infected U.S. humanitarian worker to Germany shows how the outbreak is also requiring international clinical and logistical coordination. The source material does not say where the patient acquired the infection beyond reporting that the worker tested positive in the Democratic Republic of the Congo. It also does not indicate that the patient acquired the infection in Germany.

For people outside the affected areas, the cross-border nature of the response is the practical issue to watch. The WHO report points to the need for surveillance, clinical response, infection-control measures and coordination between the Democratic Republic of the Congo, Uganda and international partners.

Vaccine evidence is limited

WHO issued emergency guidance on May 28 concerning the licensed Ebola vaccine Ervebo during Bundibugyo virus disease outbreaks. The agency said the available evidence for cross-protection against Bundibugyo virus was very limited and insufficient to reliably estimate vaccine effectiveness.

As a result, WHO recommended that Ervebo not be used programmatically for Bundibugyo outbreaks outside controlled research settings. That is not a finding that Ervebo is ineffective. It is a statement that, based on the evidence available on May 28, researchers could not reliably determine how well the vaccine protects against this virus.

The guidance instead emphasized surveillance, contact tracing, clinical management, infection prevention and control, and engagement with affected communities. WHO noted that the vaccine evidence may develop as research continues, so the May 28 guidance should be understood as based on the information available at that time.

What happens next

WHO’s latest report establishes a continuing need for cross-border monitoring and response but does not announce a new deadline or a separate final decision beyond the existing public-health emergency designation and vaccine guidance.

The immediate priorities identified in the approved WHO material are to strengthen surveillance, trace contacts, improve infection-prevention practices, support clinical care and work with communities. The July 23 update also keeps the focus on occupational exposure as the outbreak develops in the Democratic Republic of the Congo and Uganda.

The scale of the outbreak is largest in the Democratic Republic of the Congo, which had reported 1,460 confirmed cases and 452 deaths as of July 1. Uganda had reported 20 confirmed cases and two deaths as of July 2, along with one probable fatal case.

French authorities notified the WHO on June 24 that laboratory testing had confirmed Bundibugyo virus disease in a doctor returning from the Democratic Republic of the Congo. The WHO update identified one confirmed imported case in France; it did not provide a broader contemporaneous French case total.

Transmission across three countries

The primary outbreak locations include Ituri Province and other affected areas of the Democratic Republic of the Congo. WHO said Uganda’s outbreak remained epidemiologically linked to transmission originating in the Congo.

The agency described sustained transmission, including imported infections and secondary transmission among contacts and health workers. That pattern makes surveillance and contact follow-up across borders central to the response. It also creates practical challenges for health authorities trying to identify infections, monitor exposed people and reduce transmission in clinical and community settings.

The confirmed case in France demonstrates that an infection connected to the outbreak has been identified outside Africa. It does not, by itself, establish sustained community transmission in France. The available WHO update also does not support describing the outbreak as uncontrolled globally.

Why the international designation matters

The WHO declared the event a public health emergency of international concern on May 17. That designation reflects the outbreak’s cross-border implications and the need for coordinated international surveillance and response.

For countries monitoring travel-linked infections, the immediate concern is not simply the number reported in the Congo. It is the movement of infections between affected areas, the possibility of secondary transmission among contacts and health workers, and the need to maintain compatible case tracking across national health systems.

The figures are also time-sensitive. Reported totals may change as countries reconcile probable, confirmed and retrospective cases. The Uganda total, in particular, distinguishes confirmed cases and deaths from one probable fatal case, rather than treating every reported classification as equivalent.

Response priorities and vaccine limits

WHO emergency guidance issued May 28 emphasized surveillance, contact tracing, infection prevention, clinical management and community engagement during Bundibugyo virus disease outbreaks. Those measures are the agency’s stated response priorities as authorities work to identify transmission and care for patients.

The guidance also draws a firm line between Bundibugyo virus disease and Ebola virus disease caused by Ebola virus. Ervebo, the licensed Ebola vaccine, is licensed for Ebola virus disease caused by Ebola virus, not for Bundibugyo virus disease. The two diseases should not be treated as interchangeable when assessing vaccine protection.

A separate WHO technical advisory group reviewed candidate vaccines for Bundibugyo virus disease on May 28. Its recommendations included prioritizing vaccines specifically designed for Bundibugyo virus and considering both pre-exposure and post-exposure studies.

WHO also called for accelerated development and evaluation of Bundibugyo-specific or broadly protective vaccines. Those recommendations describe development and evaluation priorities, not an announcement that a Bundibugyo-specific vaccine is already licensed or broadly available.

What happens next

The next known steps are intensified surveillance, contact tracing, infection-control work, clinical management and community engagement in affected areas. Authorities will also continue monitoring the linked outbreak in Uganda and the imported case identified in France.

WHO’s vaccine-related work will proceed through assessment of candidate products and consideration of pre-exposure and post-exposure studies. Until country totals are reconciled and additional monitoring results are available, the July 3 update provides a snapshot of a cross-border outbreak rather than a final count.

The medical account does not establish that Besigye’s illness was caused by detention or mistreatment. But the courtroom episode has made a wider dispute over detention, access to counsel and military involvement in arrests more immediate.

What happened in court

According to the Associated Press, Besigye repeatedly shouted “stop” before falling backward in the dock. Court proceedings were postponed while prison guards attended to him.

AP reported that Besigye had objected to proceeding without attorneys he had selected. His main attorney, Erias Lukwago, had been detained and charged with misprision of treason, an offense that authorities say involves failing to report acts of treason.

Besigye’s wife, Winnie Byanyima, said in a post on X that he was unconscious in an intensive care unit at Mulago Hospital in Kampala and that he had cried out that he was being injured before he collapsed. Ingrid Turinawe, a confidant, told AP that she and others were not allowed to see him, although Besigye’s personal physician later saw him. A spokesperson for Uganda’s prison system did not respond to AP’s request for comment.

How the detention concerns expanded

On July 2, the U.N. secretary-general’s office said it was concerned about reports of detained political and civic actors in Uganda, including cases in which the whereabouts of some people had not been clearly established. The statement also recalled Uganda’s constitutional and international commitments concerning freedom of expression, media independence, liberty and security.

On July 16, Human Rights Watch reported that security forces had allegedly seized at least five critics of President Yoweri Museveni and his son, Gen. Muhoozi Kainerugaba, since mid-June. The organization said some were held incommunicado before being taken to police custody for prosecution.

The cases named by Human Rights Watch include lawyer Erias Lukwago, activist Miria Matembe, journalist Timothy Kalyegira, opposition figure Muwanga Kivumbi and opposition supporter Andrew Nabimanya. The report described allegations of military involvement, undisclosed detention locations, beatings, threats and other mistreatment. Those claims remain allegations or reported accounts, not final judicial findings.

Human Rights Watch said armed soldiers seized Lukwago at his Kampala home on June 15 and took him to an undisclosed location. The organization said he was later transferred to police custody. AP reported that a magistrate’s court charged him with misprision of treason. Lukwago denied the charge.

Human Rights Watch also reported that Kenyan lawyer Martha Karua was detained at Entebbe International Airport on June 22 after traveling to Uganda in connection with Lukwago’s proceedings. Authorities deported her to Kenya several hours later, according to the organization.

Why the Lukwago case matters

Detaining a lawyer connected to a high-profile political prosecution raises a direct question about whether the accused can communicate with counsel and prepare a defense without intimidation. That concern is especially significant when the lawyer’s detention is linked to the same political dispute.

AP reported that Lukwago had sought to hold Kainerugaba accountable for alleged abuses involving Besigye. Kainerugaba has denied wrongdoing and has publicly attacked critics. The Uganda Law Society called for Lukwago’s immediate release, saying the arrest was contemptuous of court processes.

What Uganda’s obligations require

Uganda is party to the African Charter on Human and Peoples’ Rights, the International Covenant on Civil and Political Rights and the Convention Against Torture. Human Rights Watch said those commitments require respect for liberty and security, protection against arbitrary arrest, access to due process and safeguards against ill-treatment. They also protect expression, association and peaceful assembly.

Those commitments do not by themselves establish that Uganda has been found liable by an international court or U.N. body in these particular cases. The narrower accountability questions are whether detainees were held in lawful places, brought promptly before a court, allowed meaningful access to counsel and protected from coercion or abuse.

What is confirmed and what remains disputed

The documented procedural developments include Lukwago’s reported seizure and charge, Karua’s reported detention and deportation, and Besigye’s collapse during court proceedings. The report that Besigye was unconscious in intensive care came from his wife and people who spoke to AP; the cited reports did not provide a full medical record or an independent medical finding.

Claims about beatings, blindfolding, threats, military responsibility and incommunicado detention come from rights reporting, relatives, lawyers, witnesses or people who say they were detained. They should be distinguished from charges filed by Ugandan authorities and from facts established by a court or independent investigation.

The prosecution says it will present evidence that Besigye and others plotted to overthrow the government. Besigye’s political party says the charges are fake and politically motivated. AP reported that President Museveni and Kainerugaba have publicly commented on the case, adding to concerns about the separation between political power, military authority and the judicial process.

What happens next

The next meaningful developments will concern Besigye’s medical care, whether he can consult lawyers of his choosing, how the court handles the treason case and whether Ugandan authorities investigate allegations involving military personnel.

For journalists, lawyers, opposition parties and civil-society groups, the broader test is whether civilian arrests remain subject to ordinary judicial safeguards. Readers should distinguish among allegations documented by rights organizations, charges filed by Ugandan authorities and facts established through court rulings or independent investigations.

Sources

• U.N. Secretary-General’s July 2 briefing
• Human Rights Watch: Uganda: Military Seizing Government Critics
• AP: Besigye collapses during treason trial

The outbreak remains concentrated in eastern Congo’s Ituri Province but has expanded across multiple health zones and five provinces. WHO says sustained transmission, population movement, displacement, insecurity and limited access to health services are making it harder to find cases, trace contacts and interrupt spread.

The distinction matters: “largest Bundibugyo outbreak” refers to the virus strain, not the largest Ebola outbreak of any type.

Many infections are outside known contact networks

Associated Press reported from Bunia on August 4 that the latest government update listed 3,802 cases and 1,707 deaths as of Tuesday. Those figures are not directly interchangeable with WHO’s earlier cumulative count because they come from a different reporting date and may use different case classifications.

WHO’s Disease Outbreak News update dated July 17 reported 2,124 confirmed cases and 828 deaths in Congo as of July 15. WHO cautioned that newly reported cases and deaths can include backlogs of samples and therefore do not necessarily represent infections acquired during the same period.

AP also reported that nearly 80% of cases were not coming from contact tracing but instead were being identified through community spread, citing Africa CDC Director-General Jean Kaseya. That wording describes how cases are being detected, not a claim that 80% of infections began outside known networks. It nevertheless points to a major surveillance problem: response teams are finding many patients who were not already linked to known contacts.

WHO’s July 17 bulletin said Congo’s cases had been reported from 46 health zones across Ituri, North Kivu, South Kivu, Haut-Uele and Tshopo provinces. Thirty-eight of those zones had reported cases within the previous 21 days. Ituri accounted for 89.6% of confirmed cases at that reporting point.

Conflict and displacement raise containment risks

The outbreak is unfolding in communities affected by armed conflict, displacement and limited access to food, water, shelter, health care and protection. Overcrowded sites for internally displaced people and frequent movement can delay testing, treatment and contact follow-up.

WHO said security incidents affecting health facilities have restricted access for response teams, disrupted surveillance and increased the risk of undetected transmission. Community deaths, mistrust and delayed care can also make it harder to conduct safe burials and identify people who may have been exposed.

Health workers face particular risks. WHO reported 119 confirmed infections among health workers in its July 17 update, including 36 deaths. The figures underscore why infection prevention and control in health facilities is central to the response: hospitals and clinics can amplify transmission when staff lack adequate training, protective equipment or safe procedures.

Response focuses on facilities, surveillance and communities

WHO and Congo’s health authorities are expanding surveillance, laboratory testing, treatment capacity, infection-prevention work and community engagement. A WHO Africa update published July 30 said infection-prevention measures had been expanded across more than 900 health facilities, with training provided to more than 1,000 health workers.

The response also includes cross-border preparedness and coordination with Uganda. Uganda began a 42-day period of enhanced surveillance on July 16, after its last confirmed patient was discharged following two negative tests. WHO says the period is required before the outbreak can be declared over, provided no new confirmed cases are detected.

Uganda has reported 20 confirmed cases and two deaths in the linked outbreak. Fifteen cases were imported from Congo and five were locally acquired, according to WHO Africa. Because transmission continues in Congo, a new imported case could reset Uganda’s countdown to day zero.

There is no approved vaccine or specific treatment for Bundibugyo virus disease. Clinical trials of investigational post-exposure drugs are under way in Ituri, while separate vaccine studies are being conducted in the United Kingdom and Canada. The studies have not established an approved vaccine or treatment.

WHO says global risk remains low

WHO assesses the risk as very high within Congo, high in Uganda and in countries sharing land borders with areas where Bundibugyo virus has been detected, and low for the rest of Africa and the world.

WHO is not recommending travel or trade restrictions against Congo or Uganda based on the information currently available. For people outside the affected region, the main significance is the need for sustained support, cross-border surveillance and reliable outbreak information—not a new global travel emergency.

Sources

• WHO Disease Outbreak News, July 17, 2026
• WHO Africa weekly outbreak report, data through July 26, 2026
• Associated Press report from Bunia, August 4, 2026

Enrollment in the PARTNERS trial began July 2, 2026, according to the World Health Organization. The randomized, controlled, adaptive platform trial is evaluating the monoclonal antibody MBP134 and the antiviral remdesivir, including whether using the two medicines together improves outcomes.

Both medicines remain investigational for Bundibugyo virus disease. Enrollment does not show that either treatment is effective, approved or suitable for patients outside the study.

How the trial works

PARTNERS may enroll patients of any age with confirmed Bundibugyo virus disease. Participants are assigned under the study protocol to treatment groups that include MBP134, remdesivir or the combination, while receiving supportive care.

That care can include oral or intravenous fluids, electrolyte replacement, oxygen support, blood-pressure management and pain control in line with WHO treatment guidance. WHO said the study data will be reviewed regularly by an independent data and safety monitoring board.

WHO is sponsoring the trial. Coordination is being led by the Democratic Republic of the Congo’s Institut National de Recherche Biomédicale, the Institute of Tropical Medicine in Belgium and the University of Oxford. The DRC Ministry of Public Health, Africa CDC, ALIMA, Médecins Sans Frontières and other response partners are also involved.

Why the research is happening during the outbreak

Bundibugyo virus disease is a distinct Ebola disease caused by the Bundibugyo virus. WHO said no treatment is currently approved specifically for it, no approved vaccine is available, and no treatment has been shown to work across all Ebola virus types.

The trial is designed to generate evidence while emergency care is being delivered. WHO said the two medicines were selected after a review of scientific evidence, including preclinical research, safety data and experience from earlier outbreak responses. That background does not establish that either medicine works against Bundibugyo virus.

The practical test will be whether the trial can measure differences in patient outcomes while maintaining supportive care and close follow-up. WHO said participants will receive follow-up for at least 28 days after enrollment.

The outbreak remains centered in Congo

WHO’s Disease Outbreak News update published July 17 reported 2,124 confirmed cases and 828 deaths in the DRC as of July 15. It said cases had been reported in 46 health zones across five provinces, with 38 health zones still active because they had reported cases within the previous 21 days. WHO also reported 119 confirmed infections among health workers, including 36 deaths.

WHO cautioned that some newly reported cases and deaths could reflect backlogs in samples and reporting, rather than infections or deaths that occurred during the same period. The outbreak is unfolding in a conflict-affected humanitarian setting where insecurity, displacement and limited access to health care complicate surveillance and treatment.

A WHO regional situation report using data through July 19 said transmission remained intense in the DRC and that the outbreak’s geographic footprint continued to expand. The same report said no new cases or secondary transmission had been reported in Uganda or France during that reporting period.

Uganda’s improving status is regional context, not a change in the main outbreak. In its July 17 update, WHO said Uganda had begun the 42-day enhanced-surveillance period after its most recent case was discharged. WHO assessed the risk as very high in the DRC, high in Uganda and countries sharing land borders with affected countries, and low globally.

What to watch next

The next meaningful milestones are enrollment progress, safety reviews, interim analyses and eventual outcome data. Those findings—not recruitment alone—will determine whether MBP134, remdesivir or the combination merits a formal recommendation or further regulatory consideration.

For people in the affected region, the immediate public-health priorities remain early diagnosis, infection prevention and control, contact tracing, supportive care and access to treatment. For readers outside the region, the trial is a research milestone during an emergency, not the approval of a new Ebola treatment or general medical guidance.

Sources

• WHO trial announcement, July 2, 2026
• WHO Africa weekly situation report, data through July 19, 2026
• Associated Press regional report

The walkout involved doctors, nurses and security staff who said they had not received two months of performance bonuses. The Associated Press reported that response officials said the payment problem was being resolved through mobile-money payments and that the backlog was expected to be cleared in the coming days. There has been no confirmation that the strike has ended.

An outbreak under operational pressure

According to DRC government data released July 24 and reported by the Associated Press, the country had recorded 2,973 confirmed cases and 1,309 deaths. Those figures may change as testing, reporting and backlog data are updated. The AP also reported that more than 100 health workers have been infected since the outbreak began, citing information from the World Health Organization.

The Bunia stoppage highlights a problem that extends beyond the virus itself: outbreak control depends on staff being present, protected and paid. Treatment centers need reliable workers to identify suspected cases, provide supportive care, collect samples, trace contacts, enforce infection-prevention procedures and support safe burials. If facilities lose staff or public trust, patients may arrive later, contacts may be missed and transmission may become harder to contain.

WHO and the U.S. Centers for Disease Control and Prevention say the response is also being complicated by limited health infrastructure, shortages of diagnostic and infection-control supplies, insecurity, violence against health workers and movement across borders.

Bundibugyo Ebola has no licensed vaccine or specific treatment

This outbreak is caused by Bundibugyo virus, a type of Ebola virus distinct from Ebola Zaire, for which licensed vaccines and specific treatments exist. WHO’s Africa office says there is currently no licensed vaccine or approved specific treatment for Bundibugyo virus disease.

That makes basic public-health operations especially important. WHO says the response is relying on early case detection, rapid diagnosis, isolation, infection prevention and control, contact tracing, supportive care, safe burial practices and community engagement. Research groups are evaluating candidate vaccines and investigational treatments, but those efforts have not yet produced a licensed countermeasure for this outbreak.

Regional risk is higher than global risk

WHO assesses the risk as very high inside the Democratic Republic of the Congo and high in Uganda and countries sharing land borders with affected countries. The agency rates the risk to the rest of Africa and the world as low. The higher regional assessment reflects ongoing transmission, cross-border movement and uneven readiness along travel and trade routes.

For U.S. readers, the CDC says no cases linked to this outbreak have been confirmed in the United States and that the likelihood of spread to the country remains very low. Travelers should rely on current CDC guidance for affected areas of the DRC and Uganda rather than assume that a low global risk eliminates the need for precautions.

The next key indicators will be whether payments restore staffing at Elikya, whether case growth slows and whether health authorities can maintain diagnosis, isolation and contact-tracing capacity in Bunia and other affected areas.

Sources

• Associated Press report on the Bunia treatment-center strike
• WHO Disease Outbreak News
• WHO Africa: DRC Ebola outbreak
• CDC Ebola outbreak situation summary

700+ deaths, but the key change is where cases and deaths are being detected

The number of deaths is the headline, but WHO and field partners are also emphasizing how the situation is being measured. Associated Press reports WHO finding that many newly reported deaths occurred in communities without reaching a health facility, and that cases are arriving through unknown chains of transmission outside contact-list pathways.

When people fall out of that chain—because they cannot get to facilities quickly, because services are disrupted, or because families hesitate to seek testing—new transmission links can be missed.

Why WHO says tracking is falling behind: surveillance, referral, isolation, and care access

ECDC’s latest update (last updated 15 July 2026 at 14:12) highlights how delays affect what investigators can confirm. ECDC says WHO Africa Region situation-report data through 5 July show 92.3% of 430 deaths investigated occurred in the community or before admission to a health facility—reflecting delays in detection, referral, isolation, and access to care.

ECDC also reports that on 14 July 2026, the Democratic Republic of the Congo (DRC) recorded 2,011 confirmed cases (including 754 related deaths) using data up until 13 July, and that 753 patients were hospitalised in isolation.

Community engagement is not optional—WHO ties it to acceptance of testing and safe handling

WHO’s Regional Office for Africa (AFRO) frames control efforts as depending on community acceptance, especially around testing decisions and safe, dignified handling of bodies. In its 14 July update from Bunia and Ituri, AFRO describes how population displacement, insecurity, and access challenges shaped the outbreak response after Ebola was declared on 15 May 2026.

AFRO describes a shift within internally displaced persons settlements: community dialogue helped families accept that deaths should be tested, and helped reduce uncertainty about whether Ebola was “real.” AFRO also says communities increasingly requested concrete response elements—investigation teams, safe and dignified burials, care, personal protective equipment, and information about treatment.

AFRO adds operational detail: between 25 May and 24 June 2026, more than 2.5 million people were reached through community-based awareness activities across Ituri, North Kivu, and South Kivu, and more than 2,800 community leaders were involved in prevention communication.

What cross-border and preparedness pressure looks like next

WHO and partner agencies say they are scaling up support to DRC response efforts—including surveillance, contact tracing, clinical preparedness and management, delivery of supplies, and cross-border preparedness—with community engagement treated as a core requirement for bringing outbreaks under control.

For the next phase, the practical “watch items” are measurable and operational: whether surveillance coverage improves (fewer cases and deaths detected outside health-facility pathways), whether referral and isolation capacity keeps up, and whether community engagement continues to translate into faster investigations, safer handling, and earlier care-seeking.

For U.S. and other English-speaking audiences, the broader relevance is straightforward: modern outbreak containment depends on the real-world ability to detect and refer people quickly—especially where insecurity, displacement, and healthcare access gaps strain every step of the response.

Sources

• WHO AFRO (14 July 2026): community engagement and time-stamped totals
• ECDC (last updated 15 July 2026 at 14:12): surveillance-and-access framing
• Associated Press: WHO-linked explanation for tracking shortfalls
• WHO emergency situation page: baseline outbreak framework

Outbreak picture in the July 1–2 snapshot

In a Disease Outbreak News briefing dated 3 July 2026, WHO reported that as of 1 July, the DRC had 1,460 confirmed cases including 452 deaths. WHO said that, compared with the previous DON update published 19 June, there were 564 additional confirmed cases including 220 confirmed deaths—with the increase partly attributed to scaled-up surveillance and testing.

WHO also reported that as of 2 July, Uganda had 20 confirmed cases including two deaths in imported cases, plus one probable case who has died. WHO said there had been no documented community transmission in Uganda, and that exposure risks were associated with healthcare settings and cross-border movements.

The DON update underscores that the response is operating in a difficult context that includes insecurity, disruption to healthcare and services, and heavy population and trade movement.

What changed on diagnostics: a new Bundibugyo test enters WHO’s EUL

On 2 July 2026, WHO said it added the first molecular diagnostic test for Bundibugyo virus to its Emergency Use Listing (EUL). WHO described the test as detecting the virus by identifying its genetic material in blood samples, aiming to help confirm infection rapidly and accurately.

WHO framed the EUL step as a way to accelerate access to reliable, quality-assured diagnostics—supporting early case detection, timely clinical care, disease surveillance, and outbreak response. WHO also described a parallel effort, alongside Africa CDC and partners, to set up a joint validation platform for multiple diagnostic options (including lab-based molecular tests, near-point-of-care molecular tests, and antigen rapid diagnostic tests).

What changed on treatments: PARTNERS trial enrolment begins

Also on 2 July 2026, WHO announced that patient enrolment opened for the PARTNERS clinical trial. WHO said PARTNERS is assessing whether two antiviral therapies—MBP134 (a monoclonal antibody) and remdesivir—can improve survival among people diagnosed with Bundibugyo virus disease, and whether combining them provides additional benefit.

WHO emphasized that the trial is set up so that research can happen alongside the response—meaning the trial is intended to generate evidence during the outbreak to inform care over time, not to imply results are already proven. WHO also said enrolled patients will receive early supportive care and be supported with close follow-up for at least 28 days after enrolment.

DRC–Uganda preparedness—and WHO’s travel/trade posture

WHO’s situation framing highlights cross-border preparedness as a core requirement: strengthening surveillance and contact tracing, improving clinical preparedness and management, ensuring delivery of supplies, and scaling community engagement. WHO’s outbreak hub also stresses that community engagement is pivotal to bringing outbreaks under control.

In the DON update, WHO addressed travel and trade directly as well. WHO said it advises against any restriction of travel to, or trade with the DRC or Uganda based on currently available information, while continuing to closely monitor and verify any measures.

What global readers should watch next

Two practical signals are likely to matter most in the coming weeks:

• Whether diagnostic capacity keeps scaling in the field, because faster confirmation can change how quickly cases are identified, isolated, and managed.
• Whether clinical research operations hold up as the outbreak evolves, since PARTNERS enrolment reflects WHO’s push to build evidence during active response rather than waiting years.

Meanwhile, independent reporting has highlighted pressure on outbreak control as suspected spread appears to move beyond the original epicenter. For example, AP reported an Ebola death toll in Congo reaching 600 and said suspected cases were recorded in provinces previously described as unaffected.

Sources

• WHO Ebola outbreak DRC 2026 situation hub (Bundibugyo-virus response priorities and operational framing)
• AP — Congo Ebola death toll reaches 600; suspected spread beyond the epicenter

What changed this week

The biggest new development is scientific rather than clinical proof: WHO said the PARTNERS trial opened enrollment on July 2 in Congo to test whether remdesivir, the monoclonal antibody MBP134, or both can improve survival. AP reported that the first participant has now been enrolled. That is an important step, but it is not evidence yet that either treatment works.

Why Bundibugyo matters

WHO says the Bundibugyo species of Ebola has no vaccine or specific treatment. For now, control depends on surveillance, contact tracing, infection prevention, clinical care, supplies, and community cooperation. People enrolled in the trial will be followed closely for at least 28 days.

Why it is hard to contain

WHO says the outbreak is unfolding in a remote but densely populated area facing humanitarian crisis, insecurity, and high population and trade movement. Those conditions make it harder to trace contacts, move supplies, isolate patients, and keep health teams ahead of each new transmission chain. WHO says it is scaling up support with Congo and Uganda on surveillance, clinical preparedness, logistics, community engagement, and cross-border readiness.

What to watch next

The main questions are whether case counts slow, whether Uganda avoids renewed spread, and whether the trial expands safely beyond the current treatment center. For readers, the practical takeaway is simple: this outbreak is still active, still cross-border, and still a test of whether health systems can move fast enough in difficult terrain.

Sources

• WHO Disease Outbreak News: Ebola disease caused by Bundibugyo virus
• AP: First Ebola treatment study in Congo

What changed

WHO’s updated outbreak notice and AP reporting on June 18-19 show the outbreak is still accelerating. AP said Africa CDC was reporting 894 confirmed cases and more than 200 deaths, underscoring how quickly the situation has escalated in less than a week. The outbreak remains centered in eastern Congo and Uganda, where health officials are tracking spread across border areas and health zones.

Why this outbreak is hard to contain

The strain at the center of the outbreak is Bundibugyo Ebola, and WHO says there is no licensed vaccine or treatment specifically approved for it. That leaves surveillance, contact tracing, laboratory testing, infection prevention, safe care, and community engagement as the main tools for slowing spread.

WHO and Africa CDC say those tools are being stretched by the conditions on the ground. Their joint plan points to the need for cross-border coordination, logistics, and protection for vulnerable populations. The response is also complicated by conflict-affected areas, mobile communities, and the difficulty of keeping track of contacts when travel and movement continue across borders.

What it means for U.S. readers

For readers in the United States, the main issue is public-health monitoring rather than domestic spread. CDC’s Ebola situation summary is the federal reference point for travel risk, outbreak geography, and ongoing monitoring tied to the Congo-Uganda emergency.

That matters because fast-moving outbreaks can prompt travel guidance changes, aid constraints, and broader international public-health coordination. Even without U.S. cases, the outbreak is a reminder of how quickly a regional health emergency can become a global planning problem.

What to watch next

The biggest questions now are whether the funding gap is closed, whether contact tracing can catch up with the spread, and whether the outbreak expands further into border regions. Watch for new WHO updates, changes in Africa CDC totals, and any travel or response measures tied to the evolving situation.

Sources

• WHO joint continental Ebola response plan
• AP latest outbreak totals